Leiden-based biotechnology company Pharming said on Friday it had made a ‘major step forward’ in the process of getting its most important medicine, Rhucin, on the market.
The company posted a loss of €6.4m in the third quarter of this year and said it had strengthened its cash position with a €70m convertible bond issue.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation